AGM Statement

5 May 2021

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Annual General Meeting (AGM) Statement

At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:

"Having closed 2020 with a strong final quarter and order book carried forward, we are pleased to report that the same pattern has continued during the first quarter of 2021. We expect further growth from the services business and TMT Pro™, assuming that the general economic background continues to return more to normality in the second half of 2021."  Ends

For further information:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.